Exubrion
1 known investors
Synovetin develops a therapeutic treatment targeting canine osteoarthritis by addressing synovial inflammation and the cytokine cascade to provide pain relief lasting up to one year. The product targets inflammation at the disease source rather than just symptom management in dogs with osteoarthritis.